-
2 months ago | 
healio.com | Michael Monostra |Richard Smith |Richard E. Pratley
Key takeaways: Diabetes Prevention Program investigators learned March 10 that government funding had been terminated. They said the program’s ongoing research may cease within weeks if funding is not restored. The future of the landmark Diabetes Prevention Program is in doubt after it lost federal funding for an ongoing long-term outcomes study and was forced to stop operations, according to the chair of the program.
-
Sep 27, 2024 | 
radcliffecvrm.com | Helen M. Colhoun |John McMurray |Richard E. Pratley |Phyo T. Htoo
EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.
-
Sep 16, 2024 | 
dom-pubs.onlinelibrary.wiley.com | Hertzel C. Gerstein |Stefano Del Prato |Renato D. Lopes |Richard E. Pratley
1 BACKGROUND/CONTEXT Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) lower HbA1c by promoting insulin secretion in response to elevated glucose (the incretin effect).1, 2 They also slow gastric emptying; reduce appetite, weight, blood pressure, low-density lipoprotein (LDL) cholesterol and serious health outcomes3; and increase heart rate and pancreatic enzymes. The degree to which these nonglycaemic effects mediate their glycaemic effects remains unclear.
-
Sep 11, 2024 | 
radcliffecardiology.com | Richard E. Pratley |Phyo T. Htoo |Julia Grapsa |Marta Sitges
Skip to main content Video Published: Views: 14 Likes: 0 Average (ratings) EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes. Interview Questions:1. What was the reasoning for this study? 2.
-
Sep 11, 2024 | 
radcliffecardiology.com | Richard E. Pratley |Julia Grapsa |Marta Sitges |Alison J Duncan
Skip to main content Video Published: Views: 22 Likes: 0 Average (ratings) EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial. Interview Questions:1. What is the reasoning behind the FLOW Trial? 2. What was the patient population and study design? 3. What are the key results? 4.
-
Sep 6, 2024 | 
radcliffecardiology.com | John McMurray |Richard E. Pratley |Julia Grapsa |Marta Sitges
Skip to main content Video Published: Views: 9 Likes: 0 Average (ratings) Join Prof Atul Pathak (Clinique Pasteur, FR) and Prof Sofie Brouwers (Olv Hospital Aalst, BE) in this video on 'Renal Denervation Takeaways From ESC Guidelines'. This video is supported by Related content
-
Aug 1, 2024 | 
jacc.org | Richard E. Pratley |Katherine R. Tuttle |Peter Rossing |Søren Bo Rasmussen
Introduction Heart failure (HF) affects an estimated 64 million people worldwide.1 The increasing global prevalence of HF is due to an aging population, as well as increasing rates of hypertension, coronary artery disease, obesity, type 2 diabetes (T2D), and chronic kidney disease (CKD).2-8 When T2D and CKD coexist, the risk for HF and mortality is increased beyond that of either condition alone.9 Therefore, developing better strategies for HF prevention and treatment in high-risk patients...
-
Jun 24, 2024 | 
healio.com | Jill Rollet |Richard Smith |Richard E. Pratley
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT2 inhibitors. The FLOW trial was not powered to observe effects for those on SGLT2s.
-
Jun 5, 2024 | 
dom-pubs.onlinelibrary.wiley.com | Ayodele Odutayo |Francesco Cosentino |Richard E. Pratley |Samuel Dagogo-Jack
CONFLICT OF INTEREST STATEMENT AO has no conflicts of interest to declare. FC has received fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ, USA), Novo Nordisk and Pfizer; and research grants from the King Gustav V and Queen Victoria Foundation, the Swedish Heart & Lung Foundation and the Swedish Research Council.
-
Aug 30, 2023 | 
healio.com | Regina Schaffer |Richard Smith |Richard E. Pratley |Jamy Ard
Source/Disclosures
Source:
Healio Interviews
Disclosures:
Eli Lilly sponsored the retatrutide and tirzepatide studies. Novo Nordisk sponsored the semaglutide studies. Ard reports consulting for Novo Nordisk and received research support and consulted for Eli Lilly. Heymsfield reports receiving personal fees from Medifast and Tanita.
